CSIR-National Institute of Science Communication and Information Resources (CSIR-NISCAIR), New Delhi
Offers
PhD Science & Technology Communication &
M.Sc. Science & Technology Communication
Last date for online application: 24.05.2018
Tuesday, May 8, 2018
Monday, May 7, 2018
Article "Research and Innovation in South African Universities: from the Triple Helix's Perspective" | by SK Patra & Mammo Muchie
Research and Innovation in South African Universities: from the Triple Helix's Perspective
Swapan Kumar Patra & Mammo Muchie, Scientometrics, 2018, Doi: 10.1007/s11192-018-2764-0
Abstract: This study explores the research and innovation in South African universities within the triple-helix framework. Patents and publications data have been used as output indicators to map the R&D activities of South African universities. The study observed that universities are the most prolific publishers and constitute about 91% of total South African publications. However, universities altogether produce only about 14% of total South African patents. Only a few universities are responsible for both patenting and publication portfolio of South Africa. The collaboration patterns from joint patents show that only about 19% patents are collaborative patents. South African public research institutes are more active in joint patents with universities followed by the foreign universities but local firms are less active in collaborative patents. The similar trends are observed in co-authored articles also. The study recommends that collaboration between universities and local firms need to be strengthened to develop technological capabilities in South Africa. South African universities need to collaborate more with the industries, particularly the local industries or institutes to achieve the 'entrepreneurial university' in terms of patents and technology transfer.
Keywords: South African universities, Triple helix, Industry–academia, linkages Social network analysis, Patents, Scientometrics
STS Article "Demythologising the 'Liberalisation' of Clinical Trial Regulations in India: A Practitioner's Perspective" | by Brijesh Regal
Demythologising the 'Liberalisation' of Clinical Trial Regulations in India: A Practitioner's Perspective
Brijesh Regal, Science, Technology and Society, 2018, 23(3): 1–22.
Abstract: Recent history of clinical trials in India has been mired in avoidable controversies. Negative public perception and consequent reactions by government and judiciary have led to a virtual blockade of clinical trials in the country. This article dispassionately analyses the fiascos that happened in the past few years, describes how folklore disseminated by media, civil society and experts created a myth about 'liberalisation' of regulations and presents facts about regulatory amendments. The causes of recent non-compliances are discussed and real fault-lines are identified. The article posits that territorial laws must remain harmonised with contemporary international standards for regulating global activities like clinical trials. Fixing what was not broken has already caused substantial harm and Indian regulators have done well by reversing the unnecessary tinkering recommended by some quasi-experts. Professional self-regulation along with implementation of existing regulations are proposed as the best solutions for gaining India's place on the global clinical trials' growth curve.
Saturday, May 5, 2018
RIS-NIAS Science Diplomacy Programme Launch Event | at IHC, New Delhi | 7th May 2018
Agenda
| 9:30 to 10:00 | Registration |
| 10:00 to 11:00 | Inaugural Session |
|
| Chair: Amb Dr. Mohan Kumar, Chairman, RIS
About the Science Diplomacy Project: Prof. Sachin Chaturvedi, Director General, RIS
Key Note Address: Shri T. S. Tirumurti, Secretary (ER), Ministry of External Affairs
Inaugural Address: Prof. Ashutosh Sharma, Secretary, Department of Science and Technology and Ministry of S&T
Vote of Thanks: Prof. D. Suba Chandran, International Strategic & Security Studies, National Institute of Advanced Studies (NIAS), Bangalore
|
| 11:00 to 11:15 | Tea Break |
| 11:15 to 12:30 | Session I: Broader Contours of Science Diplomacy |
|
| Chair: Amb. Bhaskar Balakrishnan, Former Indian Diplomat
Panelists: · Dr. R B Grover, Emeritus Professor and Former Director, Homi Bhabha National Institute, Mumbai · Dr. V Siddhartha, Former Secretary SAC-PM and Former Distinguished Scientist, DRDO · Dr. Malti Goel, Founder, Climate Change Research Institute & Former Adviser/ Scientist "G', Department of Science & Technology · Dr. Pallava Bagla, Science Journalist, NDTV and Columnist, PTI
|
| 12:30 to 13:30 | Session II: Global Experiences in Science Diplomacy |
|
| Chair: Dr. Sadhana Relia, Department of Science and Technology, Government of India
Panelists: · Ms. Tania Friederichs, R&I Counsellor, Delegation of EU to India · Mr. Pedro Ivo Ferraz da Silva, Head, Energy, Environment and Science, Technology and Innovation Section, Embassy of Brazil · Dr. Ravi Srivastava, First Secretary, Environment, Science and Technology, U.S. Embassy · Dr. Indraneel Ghose, Senior Thematic Advisor for Research, Education and Innovation, Embassy of Switzerland in India |
| 13:30 to 14:30 | Lunch
|
| 14:30 to 15:45 | Session III: Relevance of Science Diplomacy in Economic Growth |
|
| Chair: Dr. Arabinda Mitra, Department of Science and Technology, Government of India
Panelists: · Dr. Mukesh Kumar, Director, CEFIPRA · Dr Shailja Vaidya Gupta , Sci. G and In-charge (Int. Coop.), DBT · Dr. Alok R. Chaturvedi, Krannert School of Management, Purdue University, Indiana, USA · Prof. Dinesh Abrol, Professor, ISID
|
| 15:45 to 16:00 | Concluding Session |
|
| Remarks by:
Prof. D. Suba Chandran, NIAS Dr. K Ravi Srinivas, RIS
|
RSVP: Dr. Amit Kumar (Tel: +91-11-2468 2177,Ext. 187; Cell +91-9968158428; Email: research.amit[@]gmail.com, amit.kumar[@]ris.org.in)
Friday, May 4, 2018
Article "Challenges in Diabetology Research in India" by S Jena, B Mishra, A Yadav & P Desai of CSSP
Challenges in Diabetology Research in India
by Swarup Jena, Brijesh Mishra, Anamika Yadav & Pranav Desai, Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2018, 12(3): 349-355.
Abstract: Background: Diabetes emerges out to be a major epidemic in recent years that engulfs both developed and developing countries across the globe. India, a country witnessing rapid socioeconomic progress and urbanization carries a considerable share of the global diabetes burden. There has been an incongruity between disease burden and the technical capacity to make use of existing knowledge or to generate new knowledge to combat diabetes in India. Aim: This paper examines the role of different actors, organizations & institutions in shaping diabetology research in India using arrays of scientific indicators such as research output (publications and patents), research finance and role of policy-making bodies. This paper also identifies research gaps and challenges pertinent to this sector. Methodology: A combination of three methods patent data analysis, publication data analysis and primary survey corroborated with secondary data to obtain desire objectives. We made an in-depth study of the patent and publication data (2000–2016) to know the research output and direction of Indian actors, institutions and organizations in the area of diabetes research. Results: This paper identifies some key structural barriers and institutional challenges pertinent to diabetology research in India that will help in canvassing and formulating science, technology and policy guidelines for diabetology research in India. Conclusion: Multilevel intervention requires bridging the gap between knowledge and action hence policy-making should align to balance resources with innovation capabilities.
Keywords: Diabetes, Diabetology research, S&T policy, Health policy, Research evaluation
Tuesday, May 1, 2018
STS Article 'New Drugs' Approvals in India: An Institutional Perspective | by S Bhaduri & T Kipgen
'New Drugs' Approvals in India: An Institutional Perspective
by Saradindu Bhaduri, Thangminlen Kipgen, Science, Technology and Society, 2018, 23(3): 1-19.
Abstract: The approval mechanism for new drugs in India has in recent years been a subject of scrutiny and controversy in both the public sphere and academics. Frequent rollbacks in the guidelines have attracted criticisms from the industry as well. All this happens at a time, when the country aspires to catch up and keep pace with the fast-changing global regulatory norms. This article draws upon the scholarships on regulatory science and institutional theories to understand how the regulatory processes new drugs approval in India. Both strands of scholarships highlight the multidisciplinary, context-specific character of regulatory knowledge. We find that Indian regulation-making process relies heavily on regulatory knowledge built up elsewhere, potentially limiting the scope of generating its own, context-specific, regulatory knowledge through learning and capacity building. Inadequate level of deliberations in the decision-making process, dearth of documentation and a lack of connections with the larger institutional settings appear to be two other features of it. All this might explain the reasons for frequent changes, and lack of continuity, in regulation for new drugs approval in the country in recent years.
AJSTID Article "Technological Capabilities in the Indian Ayurveda Medicine Industry: Lessons for 'Industrialisation' of Alternative Medicine in the post-WTO Regime" | by A Arya & S Bhaduri
Technological Capabilities in the Indian Ayurveda Medicine Industry: Lessons for 'Industrialisation' of Alternative Medicine in the post-WTO Regime
by Abha Arya and Saradindu Bhaduri, African Journal of Science, Technology, Innovation and Development, 2018, DOI: 10.1080/20421338.2018.1455314
Abstract: This paper makes an attempt to explore technological change as well as the motivations and pattern of technological capabilities in the Indian Ayurveda medicine industry. It seeks to investigate the different kinds of learning and technological innovations taking place in the post-WTO regime in the industry to enable it to cater for the global market. The paper discusses assimilative capabilities, collaborative learning and path-dependence of the Ayurveda industry with the help of primary data collected from firms, research institutes, and individual scientists. Broadly, we find the pattern of technological capability acquisition and learning to vary with firm's size, ownership pattern, educational background of owners and firm age. We find that the categories of technological capabilities are not watertight in nature, and a firm can fall in more than one category at times. Our findings also suggest that changing formulation technologies poses a new challenge for the delivery mechanism of Ayurveda drugs, calling for a greater interdependence between medical practice and production systems. It observes the formation of region specific clusters driving collaborative learning in small and medium-sized enterprises.
Keywords: Alternative medicine policy, Ayurveda Industry, India, Learning, Pharmaceuticals, Technological Capability
Subscribe to:
Posts (Atom)